To The Moon

$Merck(MRK)$

$Merck & Co., Inc.(MRK) Soared +12.60% to $152.20: Cancer Vaccine Breakthrough Ignites 13-Year Record Rally, $155 Target in Sight 🚀💊

Latest Close Data: MRK closed at $152.20, up +12.60% (+$17.03) on 2026-08-20, marking the largest single-day gain since March 2009. The stock hit a fresh 52-week high of $153.50 intraday, just 0.85% below the all-time high zone. Volume exploded to 32.78M shares (Volume Ratio: 3.64x), dwarfing the recent daily average.

Core Market Drivers: Moderna (MRNA) and Merck's personalized mRNA melanoma vaccine (mRNA-4157/V940) achieved the primary endpoint in a Phase 3 trial for high-risk melanoma patients, preventing recurrence or spread. The breakthrough ignited a biotech sector-wide rally, with MRNA nearly doubling and MRK surging ~10% in the pre-market before extending gains. Analysts view this as a potential paradigm shift in adjuvant cancer immunotherapy, materially expanding Merck's oncology franchise beyond Keytruda.

Technical Analysis: RSI(6) hit 93.72 and RSI(12) reached 85.53, signaling extremely overbought conditions. MACD exploded higher with DIF at 3.90 vs DEA at 2.45, producing a massive histogram of +2.91 — confirming powerful bullish momentum but also raising near-term mean-reversion risk. KDJ's J-value at 100.44 reinforces the overextension.

Key Price Levels:

• Primary Support: $135.84 (prior breakout resistance, now critical retest zone)

• Strong Resistance: $153.50 (today's high and 52-week high)

• Immediate Pivot: $146.94 (today's open; must hold for continuation)

Valuation Perspective: Forward P/E surged to 49.20, far above its historical average of 23.85 and the +1 Std.Dev of 44.53. P/E (TTM) stands at 119.58, reflecting the earnings reset but signaling extreme valuation stretch relative to large-cap pharma peers.

Analyst Targets: 28 institutions cover MRK with an average target of $135.13 (range: $95–$155). Ratings: 7 Strong Buy, 17 Buy, 8 Hold. The consensus target sits 11.2% below the current price, suggesting analysts have not yet fully repriced the vaccine catalyst.

Weekly Outlook: Expect initial consolidation between $146.94–$153.50 as overbought conditions cool. A decisive close above $153.50 opens the path toward $160–$165. Failure to hold $135.84 would invalidate the breakout and trigger a retracement toward $125–$128.

⚠️ Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results. Trading involves substantial risk.

🎯$Merck & Co., Inc.(MRK) Options Strategy: Bull Call Spread (Debit Spread)

• Underlying: MRK (Merck & Co., Inc.)

• View: Cautiously bullish — explosive breakout driven by cancer vaccine catalyst, but extremely overbought short-term (RSI 93.7) with high IV percentile (95.2%)

• Strategy Type: Debit spread / defined-risk directional long

• Option Contract Portfolio:

  • Buy 1x MRK 2026-09-18 145 Call @ $8.75 (Delta: 0.769, IV: 42.2%)

  • Sell 1x MRK 2026-09-18 155 Call @ $2.635 (Delta: 0.400, IV: 37.9%)

• Max Gain & Loss:

  • Max Gain: $6,365 per spread ($10.00 spread width − $3.635 net debit) if MRK ≥ $155 at expiry

  • Max Loss: $3,635 per spread (net debit paid) if MRK ≤ $145 at expiry

• Initial Cost/Credit: Net Debit = $6.115 per share ($8.75 − $2.635) ≈ $6,115 per contract spread

🐯🪙 Share your choice and reasoning in the comments — thoughtful views may receive Tiger Coins!

Good allocation isn’t just about investing — it’s also about keeping everyday life organised.

Just like a well-balanced portfolio, the right organisation can make business trips, travel and workouts a little easier. The new Tiger Toiletry Bag features a dual-layer dry & wet separation design with plenty of space to keep your essentials neatly organised, wherever you go.

Redeem the new Tiger Toiletry Bag now in Tiger Coin Mall. https://laohu8.com/J/redeemGift?goodID=100538&type=delivery